Amir H. Lebastchi, MD, outlines his general strategy for active surveillance in prostate cancer patients, emphasizing the role of MRI and fusion-guided prostate biopsy.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.